Literature DB >> 30194149

Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells.

Toshiharu Murakami1, Tsutomu Nakazawa1, Atsushi Natsume2, Fumihiko Nishimura3, Mitsutoshi Nakamura1, Ryosuke Matsuda1, Koji Omoto1, Yoshitaka Tanaka1, Youichi Shida1, Young-Soo Park1, Yasushi Motoyama1, Ichiro Nakagawa1, Shuichi Yamada1, Kentaro Tamura1, Yasuhiro Takeshima1, Yoshiaki Takamura1, Toshihiko Wakabayashi2, Hiroyuki Nakase1.   

Abstract

BACKGROUND/AIM: Natural killer (NK) cells are considered potential antitumor effector cells. The aim of this study was to establish a novel type of a chimeric antigen receptor (CAR) NK cell line (CAR-KHYG-1) specific for epidermal growth factor receptor variant III (EGFRvIII)-expressing tumors and investigate the anti-tumor activity of EGFRvIII-specific-CAR-KHYG-1 (EvCAR-KHYG-1).
MATERIALS AND METHODS: EvCAR-KHYG-1 was established by self-inactivated lentiviral-based transduction of the EvCAR gene and magnetic bead-based purification of EvCAR-expressing NK cells. The anti-tumor effects of EvCAR-KHYG-1 were evaluated using growth inhibition and apoptosis detection assays in glioblastoma (GBM) cell lines (EGFRvIII-expressing and non-expressing U87MG).
RESULTS: The findings demonstrated that EvCAR-KHYG-1 inhibited GBM cell-growth via apoptosis in an EGFRvIII-expressing specific manner.
CONCLUSION: This is the first study to establish a CAR NK cell line based on the human NK cell line KHYG-1. Therapy with EvCAR-KHYG-1 may be an effective treatment option for GBM patients. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Chimeric antigen receptor; epidermal growth factor receptor variant III; glioblastoma; natural killer cells

Mesh:

Substances:

Year:  2018        PMID: 30194149     DOI: 10.21873/anticanres.12824

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  32 in total

Review 1.  [Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer].

Authors:  G V Kochneva; G F Sivolobova; A V Tkacheva; A A Gorchakov; S V Kulemzin
Journal:  Mol Biol (Mosk)       Date:  2020 Jan-Feb

Review 2.  Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?

Authors:  Lidia Gatto; Vincenzo Di Nunno; Enrico Franceschi; Alicia Tosoni; Stefania Bartolini; Alba Ariela Brandes
Journal:  Drugs       Date:  2022-04-09       Impact factor: 9.546

Review 3.  The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells.

Authors:  Jake Moscarelli; David Zahavi; Rachael Maynard; Louis M Weiner
Journal:  Transplant Cell Ther       Date:  2022-07-03

Review 4.  The multifaceted mechanisms of malignant glioblastoma progression and clinical implications.

Authors:  Rui Sun; Albert H Kim
Journal:  Cancer Metastasis Rev       Date:  2022-08-03       Impact factor: 9.237

Review 5.  Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies.

Authors:  Haifeng Wang; Weihuo Pan
Journal:  Mol Cell Biochem       Date:  2022-10-03       Impact factor: 3.842

Review 6.  Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review).

Authors:  Xiaobo Peng; Ling Chen; Longpei Chen; Bin Wang; Yiran Wang; Xianbao Zhan
Journal:  Exp Ther Med       Date:  2021-02-10       Impact factor: 2.447

Review 7.  CAR T Cells: A Snapshot on the Growing Options to Design a CAR.

Authors:  Astrid Holzinger; Hinrich Abken
Journal:  Hemasphere       Date:  2019-02-01

8.  Potential Role of Hsp70 and Activated NK Cells for Prediction of Prognosis in Glioblastoma Patients.

Authors:  Dominik Lobinger; Jens Gempt; Wolfgang Sievert; Melanie Barz; Sven Schmitt; Huyen Thie Nguyen; Stefan Stangl; Caroline Werner; Fei Wang; Zhiyuan Wu; Hengyi Fan; Hannah Zanth; Maxim Shevtsov; Mathias Pilz; Isabelle Riederer; Melissa Schwab; Jürgen Schlegel; Gabriele Multhoff
Journal:  Front Mol Biosci       Date:  2021-05-17

Review 9.  CAR-NK Cell: A New Paradigm in Tumor Immunotherapy.

Authors:  Faroogh Marofi; Alaa S Al-Awad; Heshu Sulaiman Rahman; Alexander Markov; Walid Kamal Abdelbasset; Yulianna Ivanovna Enina; Mahnaz Mahmoodi; Ali Hassanzadeh; Mahboubeh Yazdanifar; Max Stanley Chartrand; Mostafa Jarahian
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

Review 10.  Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer.

Authors:  May Sabry; Mark W Lowdell
Journal:  Stem Cells Transl Med       Date:  2020-05-16       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.